about
Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administrationIs the decision on the use of biosimilar growth hormone based on high quality scientific evidence? - a systematic review.Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectFactors of importance for a successful delivery system for proteins.Toxicity as a result of immunostimulation by biologics.Erythropoietin improves the healing of skin necrosis resulting from Doxorubicin extravasation in a rat modelAre biosimilars really generics?Biosimilars: the 'future' of biologic therapy?Clinical development of biosimilars: an evolving landscape.Biosimilar therapeutics-what do we need to consider?Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies.A Case of Acute Generalized Exanthematous Pustulosis after Injection of an Erythropoiesis-Stimulating Agent.A detailed examination of the antibody prevalence and characteristics of anti-ESA antibodies.Insights of biosimilars through SWOT analysis.
P2860
Q34064079-9C57A080-3D73-4265-936A-4D9591731561Q35103040-E1D6E5C8-7EA3-4099-B157-E64ABE8A8D33Q35847694-BA1505A8-68BB-40F6-ABD1-AC95BBA12066Q36316926-66E49F57-6D7E-4ADB-8578-361CBF106379Q36788414-CCA0E906-7D9C-477D-B1AD-CE5C79F5625FQ37642505-AD087390-E99E-4E8E-A71E-7B82A6B21092Q37690328-A36430B6-ADF2-40FB-8593-F376BF07E54BQ37776264-DFDF5F62-8058-4852-A2A9-1E4F1290E225Q38083094-43C2C2AD-5CDC-4F2E-BE44-910DB2F360CCQ41841849-1F75F200-6B3B-46A3-80A2-A55BE613C4D5Q41954237-64BEE832-DBBF-48DE-953C-4DE03A6BD71EQ49540696-1FB6A114-AB96-49D9-96DA-DAA195DEF99FQ50501091-30CA5DE7-F42F-4DBA-80B2-DE4060787FECQ51349679-E3C13C1A-2687-4D07-A551-6C6063ABFEEA
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Importance of biologic follow-ons: experience with EPO.
@ast
Importance of biologic follow-ons: experience with EPO.
@en
type
label
Importance of biologic follow-ons: experience with EPO.
@ast
Importance of biologic follow-ons: experience with EPO.
@en
prefLabel
Importance of biologic follow-ons: experience with EPO.
@ast
Importance of biologic follow-ons: experience with EPO.
@en
P1476
Importance of biologic follow-ons: experience with EPO.
@en
P2093
Jerome Rossert
Nicole Casadevall
P304
P356
10.1016/J.BEHA.2005.01.014
P577
2005-01-01T00:00:00Z